Encompass Health (NYSE:EHC – Get Free Report) had its price target lifted by analysts at KeyCorp from $115.00 to $117.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price objective suggests a potential upside of 15.44% from the stock’s previous close.
Other analysts have also recently issued research reports about the stock. Leerink Partners began coverage on shares of Encompass Health in a research report on Wednesday, July 10th. They set an “outperform” rating and a $100.00 price target on the stock. Stephens reiterated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Barclays dropped their price target on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. UBS Group upped their price objective on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Royal Bank of Canada boosted their target price on Encompass Health from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $107.11.
Check Out Our Latest Analysis on Encompass Health
Encompass Health Stock Performance
Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the firm posted $0.86 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Equities research analysts forecast that Encompass Health will post 4.18 EPS for the current year.
Encompass Health announced that its Board of Directors has authorized a stock repurchase program on Wednesday, July 24th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 5.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.
Insider Transactions at Encompass Health
In related news, CFO Douglas E. Coltharp sold 12,260 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.10% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. UMB Bank n.a. lifted its position in Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock valued at $31,000 after acquiring an additional 252 shares during the last quarter. V Square Quantitative Management LLC increased its position in shares of Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Oakworth Capital Inc. purchased a new stake in shares of Encompass Health in the 2nd quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock valued at $46,000 after purchasing an additional 198 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Encompass Health during the 2nd quarter worth approximately $58,000. Institutional investors and hedge funds own 97.25% of the company’s stock.
Encompass Health Company Profile
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Read More
- Five stocks we like better than Encompass Health
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What Do S&P 500 Stocks Tell Investors About the Market?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Calculate Options Profits
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.